Celyad SA (CYAD BR) stock market data APIs
€0.2272
-0.01(-4.4%)
as of October 2, 2026
Try our APIs with
free plan!
Celyad SA Financial Data Overview
Price chart is built with
Anychart
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Prev. Close
0.2272
Open
0.2199
High
0.2309
Low
0.2192
52 wk Range
0.16-0.65
Market Cap
16 849 K
P/E Ratio
11.25
Shares Outstanding
74 883 K
Revenue
7 000
EPS
0.1087
Beta
1.211
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Celyad SA data using free add-ons & libraries
Get Celyad SA Fundamental Data
Celyad SA Fundamental data includes:
- Net Revenue: 7 000
- EBITDA: 775 K
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-19
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Celyad SA News
New
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the ...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
MONT-SAINT-GUIBERT, Belgium, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issu...
Celyad Oncology reports third quarter 2023 financial results and recent business highlights
Publication of data detailing the development of our microRNA (miRNA)-based multiplex shRNA approach, which allows to down-regulate several genes simultaneously, in Molecular Therapy – Nucleic Acids...
Celyad Oncology announces the termination of its American Depository Receipt program
MONT-SAINT-GUIBERT, Belgium, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announces that Citibank, N.A., as depositary (�...
Get Celyad SA fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.